Laura Johnston

Medical oncologist, Hematologist, BMT specialist

Associate Professor of Medicine (Blood and Marrow Transplantation) at the Stanford University Medical Center

Blood and Marrow Transplant Program (BMT)

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-723-0822
Learn More About the Clinic Getting Here Make An Appointment

Hematology Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Internship: UCSF Medical Center (1990) CA

Fellowship: UCSF Medical Center (1995) CA

Residency: UCSF Medical Center (1992) CA

Medical Education: University of Minnesota School of Medicine (1989) MN

BS, University of MN, Microbiology (1982)

MD, University of MN, Medicine (1989)

Administrative Appointments

Clinic Chief, Division of Blood and Marrow Transplantation Stanford University Medical Center (2001 - Present)

BMT Cancer Care Program Physical Lead, Stanford Cancer Institute (2010 - Present)

Clinical Director, Division of Blood and Marrow Transplantation Stanford University Medical Center (2009 - Present)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Sleep Disruption in Hematopoietic Cell Transplantation Recipients: Prevalence, Severity, and Clinical Management
Jim, H. Sl., Evans, B., Jeong, J. M., Gonzalez, B. D., Johnston, L., & Palesh, O. (2014). Sleep Disruption in Hematopoietic Cell Transplantation Recipients: Prevalence, Severity, and Clinical Management. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(10), 1465-1484.

Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., & Lowsky, R. (2014). Total Lymphoid Irradiation-Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20(6), 837-843.

Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma
Minn, A. Y., Riedel, E., Halpern, J., Johnston, L. J., Horning, S. J., & Goodman, K. A. (2012). Long-term outcomes after high dose therapy and autologous haematopoietic cell rescue for refractory/relapsed Hodgkin lymphoma. BRITISH JOURNAL OF HAEMATOLOGY, 159(3), 329-339.

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
Anasetti, C., Logan, B. R., Lee, S. J., Waller, E. K., Weisdorf, D. J., & Confer, D. L. (2012). Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors. NEW ENGLAND JOURNAL OF MEDICINE, 367(16), 1487-1496.

Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., & Miklos, D. B. (2012). Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. BLOOD, 119(25), 6145-6154.

Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., & Negrin, R. (2012). Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 47(4), 581-588.

Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells
Mueller, A. Ms., Kohrt, H. Ek., Cha, S., Laport, G., Klein, J., & Shizuru, J. A. (2012). Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(1), 125-133.

Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., & Negrin, R. S. (2011). Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(11), 1679-1687.

A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies
Chen, G. L., Arai, S., Flowers, M. Ed., Otani, J. M., Qiu, J., & Miklos, D. B. (2011). A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. BLOOD, 118(15), 4070-4078.

Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen
Schaenman, J. M., Shashidhar, S., Rhee, C., Wong, J., Navato, S., & Brown, J. M. (2011). Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 17(5), 693-702.

Long-term Clinical Course of Dry Eye in Patients With Chronic Graft-Versus-Host Disease Referred for Eye Examination
Sales, C. S., Johnston, L. J., & Ta, C. N. (2011). Long-term Clinical Course of Dry Eye in Patients With Chronic Graft-Versus-Host Disease Referred for Eye Examination. CORNEA, 30(2), 143-149.

Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., & Johnston, L. (2011). Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. BONE MARROW TRANSPLANTATION, 46(2), 192-199.

Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., & Horning, S. J. (2010). Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16(8), 1145-1154.

Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure
Benjamin, J. E., Chen, G. L., Cao, T. M., Cao, P. D., Wong, R. M., & Laport, G. G. (2010). Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. BONE MARROW TRANSPLANTATION, 45(2), 303-309.

TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., & Lowsky, R. (2009). TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. BLOOD, 114(5), 1099-1109.

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease
Martin, P. J., Storer, B. E., Rowley, S. D., Flowers, M. Ed., Lee, S. J., & Weisdorf, D. (2009). Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. BLOOD, 113(21), 5074-5082.

High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience
Agarwal, R., Dvorak, C. C., Stockerl-Goldstein, K. E., Johnston, L., & Srinivas, S. (2009). High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience. BONE MARROW TRANSPLANTATION, 43(7), 547-552.

Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity
Johnston, L. (2008). Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 21(2), 177-192.

High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma
Law, L. Y., Horning, S. J., Wong, R. M., Johnston, L. J., Laport, G. G., & Stockerl-Goldstein, K. E. (2006). High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 12(7), 703-711.

Protective conditioning for acute graft-versus-host disease
Lowsky, R., Takahashi, T., Liu, Y. P., Dejbakhsh-Jones, S., GRUMET, F. C., & Strober, S. (2005). Protective conditioning for acute graft-versus-host disease. NEW ENGLAND JOURNAL OF MEDICINE, 353(13), 1321-1331.

Treatment of verruca vulgaris with topical cidofovir in an immunlocompromised patient: a case report and review of the literature
Cha, S., Johnston, L., Natkunam, Y., & Brown, J. (2005). Treatment of verruca vulgaris with topical cidofovir in an immunlocompromised patient: a case report and review of the literature. TRANSPLANT INFECTIOUS DISEASE, 7(3-4), 158-161.

Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose
Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., & Lowsky, R. (2005). Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8(+) T-cell dose. BLOOD, 105(6), 2300-2306.

CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies
Cao, T. M., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., & Lowsky, R. (2005). CD34, CD49 and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. EXPERIMENTAL HEMATOLOGY, 33(3), 279-285.

Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
Johnston, L. J., Brown, J., Shizuru, J. A., Stockerl-Goldstein, K. E., Stuart, M. J., & Chao, N. J. (2005). Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 11(1), 47-55.

Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule
Damon, L. E., JOHNSTON, L. J., Ries, C. A., Rugo, H. S., Case, D., & Linker, C. A. (2004). Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 53(6), 468-474.

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin's lymphoma;
Steven M Horwitz, Robert S Negrin, Karl G Blume, Sheila Breslin, Monic J Stuart, & Sandra J Horning. (2003). Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin's lymphoma;. Blood, 2003.

Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial
Flowers, M. Ed., Parker, P. M., JOHNSTON, L. J., Matos, A. Vb., Storer, B., & Martin, P. J. (2002). Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. BLOOD, 100(2), 415-419.

High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience
Cao, T. M., Horning, S. F., Negrin, R. S., Hu, W. W., Johnston, L. F., & Stockerl-Goldstein, K. (2001). High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: The Stanford University experience. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 7(5), 294-301.

So you want to build a Web site + A blueprint for museum professionals
Johnston, L., & JONESGARMIL, K. (1997). So you want to build a Web site + A blueprint for museum professionals. MUSEUM NEWS, 76(1), 41-44.